Logo image of ATXS

ASTRIA THERAPEUTICS INC (ATXS) Stock Fundamental Analysis

NASDAQ:ATXS - Nasdaq - US04635X1028 - Common Stock - Currency: USD

4.78  +0.02 (+0.42%)

After market: 4.78 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ATXS. ATXS was compared to 558 industry peers in the Biotechnology industry. ATXS has a great financial health rating, but its profitability evaluates not so good. ATXS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ATXS has reported negative net income.
ATXS had a negative operating cash flow in the past year.
ATXS had negative earnings in each of the past 5 years.
In the past 5 years ATXS always reported negative operating cash flow.
ATXS Yearly Net Income VS EBIT VS OCF VS FCFATXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

ATXS's Return On Assets of -34.81% is fine compared to the rest of the industry. ATXS outperforms 62.01% of its industry peers.
Looking at the Return On Equity, with a value of -37.35%, ATXS is in the better half of the industry, outperforming 72.76% of the companies in the same industry.
Industry RankSector Rank
ROA -34.81%
ROE -37.35%
ROIC N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ATXS Yearly ROA, ROE, ROICATXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATXS Yearly Profit, Operating, Gross MarginsATXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

ATXS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ATXS has more shares outstanding
There is no outstanding debt for ATXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATXS Yearly Shares OutstandingATXS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ATXS Yearly Total Debt VS Total AssetsATXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ATXS has an Altman-Z score of 4.26. This indicates that ATXS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.26, ATXS is in the better half of the industry, outperforming 77.06% of the companies in the same industry.
There is no outstanding debt for ATXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.26
ROIC/WACCN/A
WACCN/A
ATXS Yearly LT Debt VS Equity VS FCFATXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 17.39 indicates that ATXS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 17.39, ATXS belongs to the top of the industry, outperforming 91.04% of the companies in the same industry.
ATXS has a Quick Ratio of 17.39. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 17.39, ATXS belongs to the top of the industry, outperforming 91.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.39
Quick Ratio 17.39
ATXS Yearly Current Assets VS Current LiabilitesATXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

ATXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.08%, which is quite impressive.
EPS 1Y (TTM)32.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.04% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-54.05%
EPS Next 2Y-27.17%
EPS Next 3Y-18.43%
EPS Next 5Y14.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATXS Yearly Revenue VS EstimatesATXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATXS Yearly EPS VS EstimatesATXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATXS Price Earnings VS Forward Price EarningsATXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATXS Per share dataATXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as ATXS's earnings are expected to decrease with -18.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.17%
EPS Next 3Y-18.43%

More info and screens

0

5. Dividend

5.1 Amount

ATXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTRIA THERAPEUTICS INC

NASDAQ:ATXS (6/2/2025, 8:00:01 PM)

After market: 4.78 0 (0%)

4.78

+0.02 (+0.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners92.9%
Inst Owner Change-1.5%
Ins Owners0.47%
Ins Owner Change0%
Market Cap269.74M
Analysts85.33
Price Target30.98 (548.12%)
Short Float %5.65%
Short Ratio6.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.91%
Min EPS beat(2)-18.75%
Max EPS beat(2)56.57%
EPS beat(4)2
Avg EPS beat(4)7.66%
Min EPS beat(4)-18.75%
Max EPS beat(4)56.57%
EPS beat(8)3
Avg EPS beat(8)-0.93%
EPS beat(12)7
Avg EPS beat(12)3.86%
EPS beat(16)9
Avg EPS beat(16)-93.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.62%
PT rev (3m)14.62%
EPS NQ rev (1m)-18.02%
EPS NQ rev (3m)-23.24%
EPS NY rev (1m)-12.6%
EPS NY rev (3m)-18.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)-2.31
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS0
BVpS5.13
TBVpS5.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.81%
ROE -37.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.39
Quick Ratio 17.39
Altman-Z 4.26
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
EPS Next Y-54.05%
EPS Next 2Y-27.17%
EPS Next 3Y-18.43%
EPS Next 5Y14.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.19%
EBIT Next 3Y-20.11%
EBIT Next 5Y-8.05%
FCF growth 1Y-117.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-117.4%
OCF growth 3YN/A
OCF growth 5YN/A